We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Behavioral Therapy Development for Methamphetamine Abusers

This study has suspended participant recruitment.
ClinicalTrials.gov Identifier:
First Posted: November 7, 2005
Last Update Posted: June 3, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Steve Shoptaw, University of California, Los Angeles
November 3, 2005
November 7, 2005
June 3, 2013
September 2004
Not Provided
  • Craving
  • Medication compliance
  • Addiction severity
  • Psychiatric interview
  • Sex-risk behavior
Same as current
Complete list of historical versions of study NCT00249678 on ClinicalTrials.gov Archive Site
  • Depression
  • Quality of Life
Same as current
Not Provided
Not Provided
Behavioral Therapy Development for Methamphetamine Abusers
Behavioral Therapy Development for Methamphetamine Abuse
The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.
Not Provided
Phase 2
Primary Purpose: Treatment
The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings.
Behavioral: Behavior Therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
May 2007
Not Provided

Inclusion Criteria:

  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.
Sexes Eligible for Study: Male
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
R21DA018075 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Not Provided
Steve Shoptaw, University of California, Los Angeles
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: James Peck, Other University of California, Los Angeles
University of California, Los Angeles
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP